Selina Koch on Muck Rack

Selina Koch

Verified
San Francisco
As seen in: BioCentury, ACS Publications, Fm1 Today, Zephyrnet, argoviatoday.ch, baerntoday.ch, pilatustoday.ch
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Selina

Contact Selina, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Making ALS heterogeneity tractable — McGill’s Angela Genge

|
By Selina Koch 
| BioCentury
ALS clinical trials veteran Genge sees progress in pathway prioritization, progression modeling, endpoint execution and biomarker development By Selina Koch, Executive Editor Drug development in ALS has long been hampered by heterogeneity, but Angela Genge, a neurologist at McGill University, CMO of AL-S Pharma and veteran ALS trialist, argues the field may be getting closer to making that heterogeneity tractable.
Open in Who Shared Issue with article?

Biogen finds Alzheimer’s path for tau ASO despite mixed data

|
By Selina Koch 
| BioCentury
ARTICLE | Product Development Low-dose diranersen outperformed higher doses on cognition, giving the company a Phase III path and a dose-response puzzle By Selina Koch, Executive Editor Biogen cannot yet explain why the low dose of its tau-targeting therapy diranersen outperformed the high dose in a Phase II Alzheimer’s trial, but the company says it saw enough — across target engagement, cognitive signal and tolerability — to advance the low dose into Phase III.
Open in Who Shared Issue with article?

Denali approval revives surrogate-endpoint path in neuronal MPS

|
By Selina Koch 
| BioCentury
ARTICLE | Product Development Approval is first for Denali, first in the U.S. for a brain shuttle-enabled protein therapy By Selina Koch, Executive Editor The first U.S. approval of a brain shuttle-enabled protein therapy gives Denali its first product and suggests continued FDA openness to biomarker-based approvals in severe rare disease. FDA granted accelerated approval Wednesday to Denali Therapeutics Inc.
Open in Who Shared Issue with article?
See all 462 articles

Actions

Share this page

Get in touch with Selina

Contact Selina, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified